dadi trial (Firstline Biopharmaceuticals Corporation)
90
Structured Review
Firstline Biopharmaceuticals Corporation
dadi trial
Dadi Trial, supplied by Firstline Biopharmaceuticals Corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/dadi+trial/dadi+trial/10__1016_slash_s2352___3026_ascii40_19_ascii41_30235___2-108-20-8
Average 90 stars, based on 1 article reviews
Dadi Trial, supplied by Firstline Biopharmaceuticals Corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/dadi+trial/dadi+trial/10__1016_slash_s2352___3026_ascii40_19_ascii41_30235___2-108-20-8
Average 90 stars, based on 1 article reviews
dadi trial - by Bioz Stars,
2026-09
90/100 stars
Images
Related Articles
Mann-Whitney U-Test:Article Title: Treatment-free remission after first-line dasatinib discontinuation in patients with chronic myeloid leukaemia (first-line DADI trial): a single-arm, multicentre, phase 2 trial Article Snippet: Division of Hematology, Respiratory Medicine and Oncology, Department of Internal Medicine (Prof S Kimura MD, H Ureshino MD) and Center for Comprehensive Community Medicine (Prof A Kawaguchi PhD), Faculty of Medicine, Saga University, Saga, Japan; Department of Hematology and Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan (J Imagawa MD); Department of Hematology, Iwate Prefectural Central Hospital, Morioka, Japan (K Murai MD); Department of Hematology, Osaka City University Hospital, Osaka, Japan (Prof M Hino MD, H Nakamae MD); Department of Hematology and Oncology, Kyoto University Graduate School of Medicine, Kyoto, Japan (T Kitawaki MD, Prof A Takaori-Kondo MD); Division of Hematology, Department of Internal Medicine, Hyogo College of Medicine, Hyogo, Japan (M Okada MD); Department of Hematology, Hiroshima City Asa Hospital, Hiroshima, Japan (H Tanaka MD); Division of Gastroenterology and Hematology/Oncology, Department of Medicine, Asahikawa Medical University, Asahikawa, Japan (M Shindo MD); Department of Hematology, Ome Municipal General Hospital, Ome, Japan (T Kumagai MD); Department of Hematology and Respiratory Introduction BCR-ABL1 tyrosine kinase inhibitors (TKIs) enable longterm survival of patients with chronic-phase chronic myeloid leukaemia, resulting in life expectancy close to that of the general population.. The main goal of therapy for this disease is long-term survival; however, treatmentfree remission is important for patients in the chronic phase because it frees them from the adverse effects of long-term TKI administration and reduces medical costs.. The Stop Imatinib (STIM) trial was a pioneering study to investigate the possibility of discontinuation of TKIs, and revealed that about 40% of patients with chronic myeloid leukaemia who received imatinib and had sustained deep molecular response for at least 2 years could safely discontinue imatinib. |